These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36560521)

  • 1. Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination.
    Li J; Li X; Wang E; Yang J; Li J; Huang C; Zhang Y; Chen K
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
    Alidjinou EK; Demaret J; Corroyer-Simovic B; Vuotto F; Miczek S; Labreuche J; Goffard A; Trauet J; Lupau D; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
    Clin Microbiol Infect; 2023 Feb; 29(2):258.e1-258.e4. PubMed ID: 36257549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster.
    Zhao J; Zhang H; Jiang L; Cheng F; Li W; Wang Z; Liu H; Li S; Jiang Y; Li M; Li Y; Liu S; Fang M; Zhou X; Ye X; Zhao S; Zheng Y; Meng S
    Microbiol Spectr; 2024 Mar; 12(3):e0243523. PubMed ID: 38319108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses.
    Zhang L; Chen H; Yang S; Zhao Y; Shen X; He X; Ye H; Wang D; Lou J; Wang Y; Wu S
    Front Immunol; 2022; 13():990071. PubMed ID: 36203574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NM; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Vallejos OP; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo M; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    medRxiv; 2022 Feb; ():. PubMed ID: 35441179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination.
    Duan LJ; Jiang WG; Wang ZY; Yao L; Zhu KL; Meng QC; Wang BS; Li LB; Wang GL; Ma MJ
    iScience; 2022 Sep; 25(9):104886. PubMed ID: 35966041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
    Fang Z; Peng L; Filler R; Suzuki K; McNamara A; Lin Q; Renauer PA; Yang L; Menasche B; Sanchez A; Ren P; Xiong Q; Strine M; Clark P; Lin C; Ko AI; Grubaugh ND; Wilen CB; Chen S
    bioRxiv; 2022 Feb; ():. PubMed ID: 35194606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine.
    Liwsrisakun C; Pata S; Laopajon W; Takheaw N; Chaiwong W; Inchai J; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Chuensirikulchai K; Kasinrerk W
    Immun Ageing; 2022 May; 19(1):24. PubMed ID: 35610643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.
    Guirakhoo F; Wang S; Wang CY; Kuo HK; Peng WJ; Liu H; Wang L; Johnson M; Hunt A; Hu MM; Monath TP; Rumyantsev A; Goldblatt D
    J Infect Dis; 2022 Oct; 226(8):1401-1406. PubMed ID: 35723969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
    J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term variations and potency of neutralizing antibodies against Omicron subvariants after CoronaVac-inactivated booster: A 7-month follow-up study.
    Li X; Yin Y; Cui Q; Huang W; Zou Q; Shen T
    J Med Virol; 2023 Jan; 95(1):e28279. PubMed ID: 36329634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.
    Khan S; Hosseinian S; Assis R; Khalil G; Luu M; Jain A; Horvath P; Nakajima R; Palma A; Hoang A; Razzak E; Garcia N; Alger J; Kalantari M; Silzel E; Jasinskas A; Zaldivar F; Schubl S; Felgner P
    Res Sq; 2022 Dec; ():. PubMed ID: 36561177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.